Literature DB >> 12361263

Kytococcus schroeteri sp. nov., a novel Gram-positive actinobacterium isolated from a human clinical source.

Karsten Becker1, Peter Schumann, Jörg Wüllenweber, Martina Schulte, Hans-Peter Weil, Erko Stackebrandt, Georg Peters, Christof von Eiff.   

Abstract

A strain of a gram-positive, coccoid, yellow-pigmented bacterium was isolated from human blood. The bacterium was aerobic, non-encapsulated and non-motile. Phenotypically, the bacterium closely resembled Kytococcus sedentarius, but could be distinguished from this species by physiological tests and chemotaxonomic investigations. The peptidoglycan type is L-Lys-Glu2, variation A4alpha. The predominant menaquinones are MK-8 and MK-7. The major cellular fatty acids are iso-C17:1, iso-C17:0, iso-C15:0 and anteiso-C17:0. The strain contains catalase and does not produce acid from carbohydrates. The ability to hydrolyse Tween 80 and the lack of alpha-glucosidase activity are the most characteristic features. The results of comparative 16S rDNA analysis revealed that the strain represents a novel species within the genus Kytococcus, for which the name Kytococcus schroeteri sp. nov. is proposed. The type strain is strain Muenster 2000T (= DSM 13884T = CCM 4918T).

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12361263     DOI: 10.1099/00207713-52-5-1609

Source DB:  PubMed          Journal:  Int J Syst Evol Microbiol        ISSN: 1466-5026            Impact factor:   2.747


  17 in total

1.  Pneumonia and bacteremia due to Kytococcus schroeteri.

Authors:  Ola Blennow; Katarina Westling; Inga Fröding; Volkan Ozenci
Journal:  J Clin Microbiol       Date:  2011-12-07       Impact factor: 5.948

2.  Kytococcus schroeteri prosthetic valve endocarditis.

Authors:  Taher Yousri; Mohammad Hawari; Rasheed Saad; Steve Langley
Journal:  BMJ Case Rep       Date:  2010-09-29

3.  Kytococcus schroeteri pneumonia in two patients with a hematological malignancy.

Authors:  C J Hodiamont; C Huisman; L Spanjaard; R J van Ketel
Journal:  Infection       Date:  2010-03-05       Impact factor: 3.553

4.  Kytococcus schroeteri: a probably underdiagnosed pathogen involved in prosthetic valve endocarditis.

Authors:  Christian Aepinus; Esther Adolph; Christof von Eiff; Andreas Podbielski; Michael Petzsch
Journal:  Wien Klin Wochenschr       Date:  2008       Impact factor: 1.704

5.  Kocuria rhizophila adds to the emerging spectrum of micrococcal species involved in human infections.

Authors:  Karsten Becker; Frank Rutsch; Andreas Uekötter; Frank Kipp; Jens König; Thorsten Marquardt; Georg Peters; Christof von Eiff
Journal:  J Clin Microbiol       Date:  2008-07-09       Impact factor: 5.948

Review 6.  Endocarditis due to Kytococcus schroeteri: case report and review of the literature.

Authors:  Basma Mnif; Inès Boujelbène; Fouzia Mahjoubi; Radouane Gdoura; Imen Trabelsi; Sana Moalla; Imed Frikha; Samir Kammoun; Adnane Hammami
Journal:  J Clin Microbiol       Date:  2006-03       Impact factor: 5.948

7.  Augmented expression of polysaccharide intercellular adhesin in a defined Staphylococcus epidermidis mutant with the small-colony-variant phenotype.

Authors:  Nahed Al Laham; Holger Rohde; Gunnar Sander; Andreas Fischer; Muzaffar Hussain; Christine Heilmann; Dietrich Mack; Richard Proctor; Georg Peters; Karsten Becker; Christof von Eiff
Journal:  J Bacteriol       Date:  2007-04-20       Impact factor: 3.490

8.  First report of chronic implant-related septic arthritis and osteomyelitis due to Kytococcus schroeteri and a review of human K. schroeteri infections.

Authors:  J F W Chan; S S Y Wong; S S M Leung; R Y Y Fan; A H Y Ngan; K K W To; S K P Lau; K-Y Yuen; P C Y Woo
Journal:  Infection       Date:  2012-03-06       Impact factor: 3.553

9.  Kytococcus schroeteri endocarditis.

Authors:  Cécile Le Brun; Julien Bouet; Philippe Gautier; Jean-Loup Avril; Olivier Gaillot
Journal:  Emerg Infect Dis       Date:  2005-01       Impact factor: 6.883

10.  Prosthetic valve endocarditis due to Kytococcus schroeteri.

Authors:  Karsten Becker; Jörg Wüllenweber; Hans-Jakob Odenthal; Michael Moeller; Peter Shumann; Georg Peters; Christof von Eiff
Journal:  Emerg Infect Dis       Date:  2003-11       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.